Letko, Brosseau & Associates Inc Replimune Group, Inc. Transaction History

Letko, Brosseau & Associates Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$17.09 - $27.91 $261,049 - $426,325	-15,275 Reduced 67.0%	7,525 $205,000
Q4 2020 Feb 05, 2021	SELL	$23.5 - $52.65 $460,600 - $1.03 Million	-19,600 Reduced 46.23%	22,800 $870,000
Q3 2020 Nov 09, 2020	BUY	$18.85 - $27.0 $799,240 - $1.14 Million	42,400 New	42,400 $976,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Letko, Brosseau & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Letko, Brosseau & Associates Inc with notifications on news.